MARIPOSA is a clinical trial that seeks to compare the safety and efficacy of the combination treatment found in CHRYSALIS to single-agent Osimertinib for EGFR-mutated NSCLC [70]. Here, EGFR is linked to non-small cell lung carcinoma.